Loan Partners IV Portfolio Update

Executive Summary

In March 2021, Loan Partners IV held its final close with a total fund size of \$7.1 billion, including \$1.1 billion of levered equity, \$3.3 billion of unlevered equity, and \$2.7 billion of long-term asset financing



1. Actively Investing Fund¹

- As of August 24, 2022, LP IV has invested or expects to invest ~\$6.9bn across 80 investments / commitments (96% of total fund size)
- \$1.1bn invested or committed across 18 new investments and several add-on investments as of September 30, 2022
- We continue to leverage our differentiated sourcing capabilities to evaluate our pipeline of investment opportunities




Asset Management

Loan Partners IV



2. COVID-Resilient Portfolio²

- LP IV portfolio companies have been largely resilient to the COVID-19 pandemic
- No defaults to date, and no companies identified as "High Risk" due to COVID-19
- Total Unlevered Effective Yield of L+794bps³






3. Attractive Market Opportunities

- We continue to seek compelling risk-adjusted opportunities in 1st lien senior credit investments
- Given the record amounts of dry powder outstanding, private equity sponsors and corporates continue to need attractive private financing solutions
- Significant decline in year-to-date issuance in the syndicated debt markets (both HY and Leveraged Loans) has created an opening for direct lending

¹ As of August 24, 2022. ² Represents remaining portfolio as of June 30, 2022. Based on invested cost. ³ As of June 30, 2022.

Loan Partners IV Fund Profile



Note: As of June 30, 2022 unless otherwise noted. Past performance is not a guide to future performance, and there is no assurance that Goldman Sachs Asset Management Private Credit will succeed in identifying suitable investment opportunities or achieving the investment objectives set forth herein. Any information regarding investment performance is estimated only and should not be considered indicative of the actual results that may be realized or predictive of the performance of an investment product or any investment. This information should not be relied upon for the purpose of investing in or providing financing to any current or future investment product or for any other purpose. ¹ Reflects invested/commitments as of August 24, 2022, including commitments to unfunded acquisition facilities. ² Represents the combined yield on all of the Partnership's debt investments (including fully exited investments), factoring in the latest available internal exit assumptions for all remaining securities. ³ Represents at entry metrics for investments as of June 30, 2022. ⁴ Gross IRR represents the annualized rate of return before investor fees and expenses (excluding credit facility interest and expenses), factoring in the timing of investor contributions to and distributions from the Fund as well as the remaining capital balance. An individual investor's return may vary based on certain factors (including varying timing of investor contributions). ⁵ Net IRR represents the annualized rate of return to the highest fee-paying investor after investor fees and expenses, factoring in the timing of investor contributions from the Fund as well as the remaining capital balance. An individual investor's return may vary based on certain factors (including varying levels of investor fees and timing of investor contributions). ⁵ As of June 30, 2022. "Lead Lender" represents owning more than 50% of a tranche. Reflects amounts held by Goldman Sachs Asset Management Private Credit fund vehicles, managed accounts and the GS balance s

Loan Partners IV Portfolio Update

Summary of Investments (\$ in millions)

Investment	Initial Investment Date	Final Exit Date	Investment Cost	Realized Proceeds	Estimated Value	Realized & Estimated Value
Europe						_
Advanced Computer Software Group, Plc	11/2020		\$46	\$5	\$44	\$49
All4Labels Group GmbH	02/2020		158	18	160	178
Anticimex AB	11/2021		48	2	47	49
AR Packaging Group AB	02/2020	11/2021	65	72	0	72
Biofarma Group	03/2022		46	0	46	46
Casa Optima	04/2022		100	1	100	101
Colosseum Dental Group AS	10/2020		108	5	109	114
Desotec N.V.	05/2021		48	3	46	49
Docu Nordic Group Holding AB	02/2021		64	41	29	70
Dutch Ophthalmic Research Center	12/2021		76	2	74	76
Element Materials Technology	12/2021	07/2022	63	2	64	66
evidia Holding GmbH	08/2021		78	3	75	78
Evri	11/2020		156	12	159	171
FNZ Group Services Ltd.	11/2021		35	1	35	36
H.L. Barentz B.V.	02/2020		118	45	87	132
HTL Biotechnology	02/2022		76	2	76	78
IAD International	04/2021		120	8	116	124
Industria Chimica Emiliana	04/2022		68	0	69	69
International Schools Partnership Limited	07/2021		63	3	59	63
Internationella Engelska Skolan AB	03/2021		139	11	135	145
Medivet Group Limited	10/2021		91	3	90	93
Miller Insurance Services LLP	02/2021		68	6	66	72
Nactarome Group	02/2022		76	0	78	78
OMNES Education	12/2021		57	1	56	57
Pharmathen S.A.	01/2022		87	2	86	89
PIB Group Limited	12/2021		32	2	29	31
Premier Technical Services Group Limited	08/2021		155	8	149	157
Qualitest Ltd	03/2021		197	14	196	210
Schur Flexibles Gmbh	12/2020	09/2021	136	150	0	150
Septeo	12/2020		115	9	114	123
Serrala Group GmbH	11/2021		41	2	40	42
Solabia Group	12/2021		81	2	79	81
Tentamus Group GmbH	09/2021		98	3	95	98
Tinsa Group	12/2021		83	2	81	84
TKE	07/2020		48	5	53	57
Veonet	04/2020	03/2022	118	137	0	137
Visma AS	09/2020		98	0	113	113
Wella AG	11/2020		152	55	104	159
Total Europe (38)			\$3,406	\$637	\$2,960	\$3,597

Note: Past performance is not indicative of future results, which may vary. The value of investments and income derived from investments will fluctuate and can go down as well as up. Any information regarding investment performance is estimated only and should not be considered indicative of the actual results that may be realized or predictive of the performance of an investment product or any investment. This information should not be relied upon for the purpose of investing in or providing financing to any current or future investment product or for any other purpose. Reflects investments / commitments as of July 18, 2022. The investment agreements with respect to committed transactions include customary representations, warranties and covenants of the parties as well as termination provisions and closing conditions. The closing of such transactions is contingent on the satisfaction or waiver of such closing conditions. No assurances are provided that such conditions will be met or that the proposed transactions will be consummated within the proposed time frame, or at all. Pending investment amounts are subject to change. Harvested investments in bold.¹ Realized proceeds include principal repayments, fees and interest received from investments, and exclude credit facility interest expense. Affiliates of Goldman Sachs receive servicing fees and may be entitled to supplemental servicing fees on net gains from LP IV. Amounts set forth above are not reduced for such fees. ² Estimated values are based upon available information and do not necessarily represent amounts which might ultimately be realized. Estimated value includes accrued interest receivable. ³ Formerly Ober Scharrer Gruppe GmbH.

Loan Partners IV Portfolio Update

Summary of Investments (\$ in millions)

Investment	Initial Inv. Date	Final Exit Date	Investment Cost	Realized Proceeds	Est. Value	Realized & Est. Value
Americas	IIIV. Date	Date	0031	11000000	Value	Value
Compusoft + 20-20 Technologies, Inc.	06/2022		\$44	\$0	\$44	\$44
Adenza	12/2020		200	18	197	216
Agiliti Health, Inc.		04/2021	33	38	0	38
AMCS	06/2022		35	0	36	36
Apex Service Partners	04/2022		22	0	21	22
Area Wide Protective. Inc.	12/2020		79	10	80	90
Boasso Global	07/2021		105	7	102	109
Caliber Collision	05/2020		24	4	24	28
Calypso Technology, Inc.	02/2020	07/2021	113	125	0	125
Canadian Veterinary Network, Inc.	07/2020		134	17	137	154
CHG Healthcare Services, Inc.	05/2020	09/2021	15	18	0	18
Curriculum Associates, LLC	05/2021		138	8	139	147
Eagle Family Foods Group LLC	07/2021		139	8	136	145
Ferraro Foods, Inc.	04/2021		168	14	163	177
Galway Insurance Holdings	06/2020	09/2021	53	63	0	63
Heartland Dental Care, Inc.	08/2020		40	7	40	47
IDS Group, Inc.	06/2021		81	6	81	87
Integrity Marketing Group, LLC	04/2021		94	7	93	101
International Data Group, Inc.	11/2021		105	4	104	108
Marcone	01/2022		37	1	36	37
Nitel, Inc.	12/2021		52	2	52	54
Osmose Utilities Services, Inc.	06/2021		52	4	51	55
Pinnacle Dermatology	12/2021		40	1	40	42
QuVa Pharma, Inc.	04/2021		71	6	68	75
Radwell International	04/2022		81	1	81	83
RSC Insurance Brokerage, Inc.	09/2020		49	3	50	53
SpecialtyCare, Inc.	06/2021		127	8	125	132
Sphera	09/2021		74	5	72	76
StandardAero Aviation Holdings, Inc.	07/2021		114	8	110	118
Technimark LLC	07/2021		30	2	29	32
Valet Living Inc.	09/2020		80	11	79	90
Valtir	12/2021		48	2	47	49
Total Americas (32)			\$2,478	\$410	\$2,238	\$2,648
<u>Australia</u>						
Advanced Personnel Management	07/2020	07/2022	\$42	\$6	\$42	\$48
The Entertainment and Education Group	04/2022		41	0	42	42
Total Australia (2)			\$83	\$6	\$84	\$90
Foreign Currency Valuation Adjustment⁴	N/A			\$(25)	\$ 57	\$ 32
Total Global Portfolio as of June 30, 2022 (72)			\$5,967	\$1,028	\$5,339	\$6,367

Investment	Initial Inv. Date	Investment / Committed Cost
Envirotainer International AB	07/2022	\$36
123Dentist	08/2022	32
Excelitas Technologies	08/2022	36
SNFL	Pending	108
Odealim	Pending	47
Advarra	Pending	39
Informa Pharma Intelligence	Pending	45
TeamSystem	Pending	34
Acquisition Credit Facilities	Various	\$508
Pro Forma Investments / Commitments as of A	\$6,851	
		

Note: Past performance is not indicative of future results, which may vary. The value of investments and income derived from investments will fluctuate and can go down as well as up. Any information regarding investment performance is estimated only and should not be considered indicative of the actual results that may be realized or predictive of the performance of an investment. This information should not be relied upon for the purpose of investing in or provided on any current agreements with respect to committed transactions include customary representations, warranties and covenants of the parties as well as termination provisions and closing conditions. The closing of such transactions is contingent on the satisfaction or waiver of such closing conditions. No assurances are provided that such conditions will be met or that the proposed transactions will be consummated within the proposed time frame, or at all. Pending investment amounts are subject to change. Harvested investments in bold. Realized proceeds include principal repayments, fees and interest received from investments, and exclude credit facility interest expense. All illustrates the proposed transaction on the gains from LP IV. Amounts set forth above are not reduced for such fees. Estimated values are based upon available information adjustment includes all net realized / unrealized foreign exchange gains/losses on non-US dollar denominated investments arising from changes in exchange rates and all realized/unrealized gains/losses on foreign exchange hedges, including the Levered Partnership's Class A Notes/Bank Loan. The Foreign Currency Valuation Adjustment is not pro rata between the Levered Partnership's under the Class A Notes/Bank Loan as a hedge.